title: A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation.
abstract: Sixty-nine depressive patients (DSM III criteria: 296.2, 296.3, 296.5, 300.4) were treated with 40 to 60 mg citalopram (CIT) daily for 4 weeks. Among them, 45 responded to treatment (improvement > 50% on the 21-item Hamilton Rating Scale for Depression [HAM-D]) and continued their treatment for another week before being released from the study. The 24 nonresponders were randomized and comedicated under double-blind conditions with lithium carbonate (Li) (2 x 400 mg/day) (CIT-Li group) or with placebo (CIT-Pl group) from days 29 to 35. For days 36 to 42, the patients of both subgroups were treated openly with Li (800 mg/day) in addition to the ongoing CIT treatment. On day 35, 6 of 10 patients responded to the CIT-Li combination, whereas 2 of 14 patients only responded to the CIT-Pl combination. This group difference reached significance (p < 0.05) on day 35 with lower HAM-D total scores in the CIT-Li group. No evidence was seen of a pharmacokinetic interaction between CIT and Li, and this combination was well tolerated. Patients were phenotyped with dextromethorphan and mephenytoin at baseline and at day 28. As evaluated at baseline, three patients (responders) were poor metabolizers of dextromethorphan and six patients (three responders and three nonresponders) of mephenytoin. On day 28, the ratio CIT/N-desmethylCIT (DCIT) in plasma was significantly higher in poor than in extensive metabolizers of mephenytoin (p = 0.0001), and there was a significant positive correlation between the metabolic ratio of dextromethorphan and the ratio DCIT/N-didesmethylCIT in plasma (p < 0.001). These findings illustrate the role of CYP2D6 and CYP2C19 in the metabolism of CIT. It can be concluded that Li addition to CIT is effective in patients not responding to CIT alone without any evidence of an accentuation or provocation of adverse events.
authors.affiliation: Département Universitaire de Psychiatrie Adulte, Prilly-Lausanne, Switzerland.
authors.forename: P
authors.initials: P
authors.lastname: Baumann
authors.forename: R
authors.initials: R
authors.lastname: Nil
authors.forename: A
authors.initials: A
authors.lastname: Souche
authors.forename: S
authors.initials: S
authors.lastname: Montaldi
authors.forename: D
authors.initials: D
authors.lastname: Baettig
authors.forename: S
authors.initials: S
authors.lastname: Lambert
authors.forename: C
authors.initials: C
authors.lastname: Uehlinger
authors.forename: A
authors.initials: A
authors.lastname: Kasas
authors.forename: M
authors.initials: M
authors.lastname: Amey
authors.forename: M
authors.initials: M
authors.lastname: Jonzier-Perey
mesh_terms: D000328:Adult; D000928:Antidepressive Agents / Q000008:administration & dosage*; D001189:Aryl Hydrocarbon Hydroxylases; D015283:Citalopram / Q000008:administration & dosage* / Q000097:blood / Q000378:metabolism*; D065731:Cytochrome P-450 CYP2C19; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics / Q000378:metabolism*; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics / Q000378:metabolism*; D003866:Depressive Disorder / Q000188:drug therapy* / Q000235:genetics; D003915:Dextromethorphan / Q000378:metabolism; D004311:Double-Blind Method; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D016651:Lithium Carbonate / Q000008:administration & dosage*; D008297:Male; D008617:Mephenytoin / Q000378:metabolism; D008875:Middle Aged; D006899:Mixed Function Oxygenases / Q000235:genetics / Q000378:metabolism*; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage*
chemical_list: D000928:Antidepressive Agents; D001189:Aryl Hydrocarbon Hydroxylases; D015283:Citalopram; D065731:Cytochrome P-450 CYP2C19; D019389:Cytochrome P-450 CYP2D6; D003577:Cytochrome P-450 Enzyme System; D003915:Dextromethorphan; D016651:Lithium Carbonate; D008617:Mephenytoin; D006899:Mixed Function Oxygenases; D017367:Selective Serotonin Reuptake Inhibitors; C045793:CYP2C19 protein, human